TG Therapeutics outlines $825M–$850M BRIUMVI 2026 guidance while accelerating subcutaneous program
Earnings Call Insights: TG Therapeutics (TGTX) Q4 2025 Michael Weiss, Chairman, CEO & President, stated that 2025 was a...
Tag: TGTX
TG Therapeutics GAAP EPS of $0.14 misses by $0.21, revenue of $192.6M misses by $0.74M
TG Therapeutics press release (TGTX): Q4 GAAP EPS of $0.14 misses by $0.21. Revenue of $192.6M (+78.0% Y/Y) misses by...
TG Therapeutics Q4 2025 Earnings Preview
TG Therapeutics (TGTX) is scheduled to announce Q4 earnings results on Thursday, February 26th, before market open. The...
Top Quant rated bullish mid cap stocks among companies with high short interest
Hedge funds aggressively ramped up record-breaking short positions on U.S. stocks last week, the highest since 2016 per...
TG Therapeutics reports Preliminary Q4 results
TG Therapeutics press release (TGTX): Q4 BRIUMVI U.S. net product revenue expected to be approximately $182 million and $594...
Best Quant-rated small- and mid-cap healthcare stocks as LLY hits $1T in market cap
As Eli Lilly (LLY) becomes the first pharmaceutical company to hit $1T in market cap, Seeking Alpha takes a look at some of...
Roche posts late-stage trial wins for new multiple sclerosis therapy
Roche (OTCQX:RHHBY) shares closed ~4% higher in Europe on Monday as the maker of Ocrevus multiple sclerosis therapy...
TG Therapeutics raises BRIUMVI 2025 revenue guidance to $585M while advancing subcutaneous pipeline
Earnings Call Insights: TG Therapeutics (TGTX) Q3 2025 CEO Michael Weiss reported, "Our flagship product, BRIUMVI for...
TG Therapeutics EPS of $2.43, revenue of $161.71M beats by $9.54M
TG Therapeutics press release (TGTX): Q3 EPS of $2.43 may not be comparable to consensus of $0.21. Third quarter results...
TG Therapeutics announces $100M share buyback program
TG Therapeutics (NASDAQ:TGTX) announced on Wednesday that its board authorized a new share repurchase program to buy back...